Latest News

A complete system for lead-to-answer screening in ion channel assays

Alameda, CA - Fluxion Biosciences, a global leader in automated patch clamp systems for ion channel drug discovery, today announced the release of an integrated and affordable solution for simplifying automated ion channel assays.

Ion channels are the third most significant drug target, after kinases and GPCRs. However, ion channels remain an underserved target class due to the significant challenges in screening and drug...

Potential treatments identified that may offer improved outcomes in COVID-19 patients with increased thrombus formation

Alameda, Calif. -- Fluxion Biosciences announced two recent publications on COVID-19 and its ability to lead to high levels of platelet coagulation and an increased risk of thrombosis. The first study, published by a team at the University of Pennsylvania School of Medicine, was published in May 2021 as a preprint in bioRxiv, and is titled “Signaling through FcgRIIA and the...

356-patient concordance study confirms performance using head-to-head testing vs. droplet digital PCR

Alameda, CA, June 16, 2021 - Fluxion Biosciences announced the publication of a paper on ERASE-Seq™ liquid biopsy with molecular amplification pools (MAPs). The paper, "Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools", published in Nature Scientific Reports on May 24, is co-authored by researchers at Fluxion and the Hospices Civils de...

All the benefits of the industry leading BioFlux cell analysis platform, now in a configuration every lab can afford.

Alameda, CA - Fluxion Biosciences, the leading developer of live cell analysis systems that feature physiological shear flow, has just announced the release of BioFlux One, its most affordable BioFlux system. 

The BioFlux One system is the solution for labs that run flow cell experiments but don't need 2-phase flow. It provides all the benefits of the industry standard BioFlux...

New panels target EGFR Pathways, clinically relevant myeloid genes, and TP53Alameda, CA, December 10, 2019 - Fluxion Biosciences announced today the launch of three new Spotlight targeted NGS liquid biopsy panels: Spotlight Comprehensive TP53, Spotlight EGFR Pathway, and Spotlight Myeloid. These new panels complement Fluxion’s current pan-cancer panel, Spotlight 59. Each of the panels has been validated with Fluxion’s ERASE-Seq variant caller, and they are intended for use with cfDNA, CTCs, and...

Patented ERASE-Seq approach delivers ultra-high sensitivity somatic mutation detection using molecular amplification pools (MAPs) and background error correction

Alameda, CA, December 3, 2019 - Fluxion Biosciences announced today a foundational patent has been issued for its ERASE-Seq technology, US patent 10,294,518, ‘Methods and Systems for Ultra-sensitive Detection of Genomic Alterations’. The ERASE-Seq technology and testing approach leverage inter-sample statistical analysis, rather than...

Grant will support development of Spotlight™ NIPT, a novel single-cell NGS assay for non-invasive fetal testing using the mother’s blood sample

Alameda, CA, October 2, 2019 - Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced that it has received a National Institutes of Health grant for development of its novel Spotlight™ NIPT non-invasive prenatal test (NIPT). The Phase I grant will have a duration of 6-9 months, with...

Our CTO, Dr. Cristian Ionescu-Zanetti, presented this webinar on Thursday, August 1. The webinar recording is now available at https://attendee.gotowebinar.com/register/7692209037115233805.

Webinar overview

Low signal-to-noise cfDNA-based liquid biopsies require improvements in sensitivity and specificity to provide the level of performance required for clinical utility. A common solution is the use of unique molecular identifiers (UMIs) to track individual molecules being amplified, but UMIs...

Participation will help advance liquid biopsy adoption by collaborating among key industry stakeholders

Alameda, CA, June 12, 2019 - Fluxion Biosciences, a leading developer of liquid biopsy solutions, today announced that it has joined the BloodPAC (Blood Profiling Atlas in Cancer) industry consortium. BloodPAC (www.bloodpac.org) includes major stakeholders in the development and clinical adoption of liquid biopsies, including test developers, cancer centers, pharmaceutical companies, and...

Glycocalyx research utilizing the BioFlux System

The glycocalyx is a covering surrounding the membrane of certain bacteria, epithelia, and other cells. It is composed of glycoproteins and glycolipids, as well as matrix proteins secreted from the cell. In addition to physically protecting the cell, its functions include mediation of cell-cell and cell-ECM interactions. Glycocalyx research has been progressing in recent years, extending from the human cardiovascular system to biofilm research. ...

Publications demonstrate depth and breadth of Fluxion’s liquid biopsy technologies

Fluxion has been pioneering liquid biopsy technologies since 2009, so it’s not surprising that researchers globally use the technologies for ground-breaking research. The publications highlighted here demonstrate the breadth and depth of applications being developed using our platforms.

2019 Publications

https://www.ncbi.nlm.nih.gov/pubmed/30602616

The authors were able to extract CTCs using IsoFlux and to...

Grant will support advanced development and clinical validation with researchers at Cleveland Clinic 

Alameda, CA, February 26, 2019 - Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced that it has received a National Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant will have a duration of 9 months, with clinical support from the lab of Dr. Omar Mian at the...

Custom panels can be now be validated and analyzed using ERASE-Seq variant caller

Alameda, CA, January 10, 2019 - Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced the launch of custom panel development services. Fluxion can validate an existing panel using ERASE-Seq, or can develop and supply custom kits based on the lab’s requirements.

Most current liquid biopsy technologies require chemical tags or “molecular barcodes”...

New plate format allows users to test bacterial growth on a variety of substrates

Alameda, CA, January 10, 2019 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has launched a new BioFlux plate format that allows users to test custom substrates.

A promising approach to preventing bacterial colony formation on medical devices is the use of surfaces that are resistant to bacterial...

Digital Cell Imaging System for live cell analysis under shear flow

Alameda, CA, December 10, 2018 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has launched the BioFlux DCIS Digital Cell Imaging System.

The BioFlux DCIS provides a complete solution for live cell imaging under physiological conditions. The easy-to-use cell imaging system been designed with advanced capabilities to...

New controller option allows control of 2 independent gas inputs for developing gas concentration gradients

Alameda, CA, September 1, 2018 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has launched a new BioFlux capability for dual gas control.

Under normal physiological conditions, oxygen plays an essential role in a host of cellular processes such as metabolism, cell growth,...

New plate format utilizes silicone rubber construction to allow detailed study of indwelling catheter bacterial biofilms

San Francisco, CA, December 14, 2017 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has launched a new BioFlux plate for studying infections caused by the long-term use of catheters. The new plates are available immediately.

Silicone rubbers such as PDMS...

Inter-sample digital processing improves sensitivity and specificity of variant calling; results superior to molecular barcoding approaches

Alameda, Calif. -- Fluxion Biosciences announced today the publication of peer-reviewed research on its ERASE-Seq™ bioinformatics solution. The paper, titled “ERASE-Seq: Leveraging Replicate Measurements To Enhance Ultralow Frequency Variant Detection In NGS Data”, was published in PLOS One on April 9 and is co-authored by researchers at Illumina and Swift...

Cloud-based ERASE-Seq delivers ultra-high sensitivity somatic mutation detection using background error correction and statistical noise reduction

Alameda, Calif. -- Fluxion Biosciences announced today that its ERASE-Seq™ bioinformatics solution can now be utilized for variant calling from a wide range of targeted cancer panels. Until now, ERASE-Seq was limited to use on Fluxion’s 59-gene Spotlight 59 Cancer Panel. ERASE-Seq is now available for use with Swift Biosciences’ Accel Amplicon™ 56G...

Harvard Bioscience will distribute the IonFlux and BioFlux Systems, targeting the electrophysiology and live cell imaging markets.

San Francisco, CA, November 13, 2017 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has signed a distribution agreement with Harvard Biosciences. The distribution agreement covers Fluxion’s BioFlux™ and IonFlux™ platforms for sale to Harvard Bioscience’s...

Harvard Bioscience will distribute the IonFlux and BioFlux Systems, targeting the electrophysiology and live cell imaging markets.

San Francisco, CA, November 13, 2017 - Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has signed a distribution agreement with Harvard Biosciences. The distribution agreement covers Fluxion’s BioFlux™ and IonFlux™ platforms for sale to Harvard Bioscience’s...

BEDFORD, MASSACHUSETTS – April 7, 2017 – Fluxion Biosciences, INC and Formulatrix have announced a partnership to provide electrophysiologists with an efficient and cost-effective workflow for high-throughput patch clamp studies.  Fluxion has begun promoting the Mantis, designed and manufactured by Formulatrix, as an accessory that further enhances the flexibility and data quality associated with their IonFlux Mercury Automated Patch Clamp System.  By adopting this non-contact microfluidic...

Genetracer Biotech will utilize Fluxion’s IsoFlux circulating tumor cell (CTC) system to provide NGS-based liquid biopsy services for lung and colon cancers

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences announced today that Genetracer Biotech of Santander, Spain has been appointed as a Certified Service Provider for Fluxion’s IsoFlux CTC Liquid Biopsy System. The IsoFlux system will be used in Genetracer Biotech’s novel liquid biopsy workflows for detection of mutations relevant to lung...

December 7, 2016

Fluxion Biosciences has introduced a new interface expanding the compatibility of their BioFlux quick release microfluidic interface to the Invitrogen™ EVOS™ FL Auto System from Thermo Fisher Scientific. The quick release interface enhances throughput and ease of use by reducing microfluidic plate mounting times.  This type of interface is custom-fitted to the automated microscopy stage, and offers the best in compatibility by accepting all BioFlux well plate microfluidic...

2016-11-3South San Francisco, Calif. – Fluxion Biosciences announced today the release of a second generation of its IonFlux automated patch clamp family of products.  IonFlux Mercury will  replace and update the existing IonFlux product family. While IonFlux systems were previously  distributed by Molecular Devices, the new product line will be sold direct by Fluxion Biosciences and its partners.

IonFlux systems are being used all over the world in industry and academic laboratories and are...

October 27, 2016

The Spotlight 59™ panel and novel ERASE-Seq methodology are designed for ultra-sensitive variant detection from CTCs and cfDNA

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. the launch of the Spotlight 59 Oncology Panel. Designed for the detection of mutations from liquid biopsy samples, the Spotlight™ 59 Oncology Panel is a turnkey solution, offering ultra-sensitive variant detection from low input quantities of DNA. The high sensitivity of Spotlight 59 makes it...

September 14, 2016

New imager automates imaging and detection of CTCs recovered from the IsoFlux Liquid Biopsy System

September 14 2016

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has launched a new imaging system, the IsoFlux Cytation Imager, designed to work exclusively with the IsoFlux Liquid Biopsy System and CTC Enumeration Kit. The IsoFlux Cytation Imager comes pre-configured with all components and software required for automated CTC image...

August 3 2016

South San Francisco, Calif. – Fluxion Biosciences announced the release of a user publication demonstrating the efficacy of the IonFlux HT automated patch clamp system as a key component of the drug discovery process. Neusentis (Pfizer Ltd.) published a study investigating the effectiveness of discovering positive allosteric modulators (PAMs) of glycine receptors.  The publication highlighted the use of a discovery workflow using a fluorescent membrane potential primary screen,...

A fully automated and affordable alternative to manual patch clamp

[ MORE INFORMATION ]

" data-test="image-block-inline-outer-wrapper" >

" style=" max-width:231px;

" >

class=" sqs-block-image-link

" href="/s/IF-C-Handout-Rev-A.pdf"

>

April 29, 2016

UT Health will utilize Fluxion’s IsoFlux System for development of novel liquid biopsy approaches to improve diagnosis and treatment of cancer from a routine blood draw

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences announced today that it is collaborating with the University of Texas Health Science Center (Houston) to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients. The laboratory of Dr. Robert Amato is utilizing...

March 28, 2016

Extended Flow can maintain cells under perfusion for up to three weeks

South San Francisco, Calif., March 16, 2016 -- Fluxion Biosciences announced today that it has launched its BioFlux Extended Flow module for live cell analysis. The module consists of a new 6-well plate consumable and interface; it is now available and shipping to customers.

BioFlux provides the ability to emulate physiological flow and shear forces in an in vitro model, while maintaining a convenient well...

South San Francisco, Calif. – Genentech’s recent publication “Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design”, details the discovery of a new NMDA receptor PAM with potential implications for neurological disorders such schizophrenia. The drug was developed with the help of unique capabilities provided by the IonFlux HT automated patch clamp (APC) system.

N-methyl-D-asparate receptors (NMDAR) are...

February 17, 2016

New kits add additional markers to improve capture efficiency for a wide variety of circulating cancer cells, including cells that have undergone epithelial-to-mesenchymal transition (EMT)

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has launched two new kits for enhanced CTC isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system. The new kits include the Enhanced Recovery Kit and the EMT Kit. The...

The IonFlux system's unique capabilities allow for the execution of otherwise very difficult assays. Its distinctive characteristics with fast in-plate solution exchange, continuous flow of external buffers, and best-in-class temperature control, permit not only fast screening of ion channel activity but also non-traditional assays such as analysis of cell membrane conductivity in the presence of external stressors. Below are some examples demonstrating the range of flexibility IonFlux systems...

October 15, 2015

Integration combines benefits of BioFlux physiological cell interaction analysis with the compactness of the Etaluma Lumascope

August 13, 2015 – (South San Francisco, CA) Today Fluxion Biosciences and Etaluma announced a co-marketing agreement between the two companies. The agreement joins the power of Fluxion’s Bioflux System for cellular assays with Etaluma’s next generation Lumascope inverted microscopes, in applications where space limitations are of importance.  Together,...

April 16, 2015

New kits enables broader capture of tumor cells from blood using epithelial and mesenchymal markers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences announced the introduction of the IsoFlux™ EMT Enrichment Kit for the isolation of rare circulating tumor cells (CTCs) from blood samples. The new kit works with the IsoFlux System instrument and specifically targets cells with both epithelial and mesenchymal properties. This represents a breakthrough in liquid...

May 27, 2015

South San Francisco, CA (May 27, 2015) – In advance of the 2015 American Society of Clinical Oncology Annual meeting, Fluxion Biosciences, Inc. and Swift Biosciences, Inc. announced a new workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The jointly-developed workflow utilizes Fluxion’s IsoFlux™ System for circulating tumor cell (CTC) enrichment and Swift’s Accel-Amplicon™ technology for high sensitivity variant detection using...

February 20, 2015

Bozeman, MT (February 16, 2015) — Golden Helix, Inc. and Fluxion Biosciences, Inc. announced their collaboration in a value-added reseller relationship today, focused on the VarSeq software application for next-generation sequencing (NGS) analysis.

"Providing our global client base with a method to study tumor DNA in the circulation is a capability we are proud to offer", said Jeff Jensen, CEO of Fluxion. "Offering the VarSeq software to our customers is a critical step toward...

Paralytic shellfish poisoning (PSP) is a serious risk to human consumption of mollusks. Considering that the main target for these toxins is Nav channels, most studies screening for these compounds focused on binding assays instead of patch clamp. A study from Universidad de Santiago de Compostela in Spain focused on developing a screening assay for toxicity equivalence factors of PSP analogs using automated patch clamp (APC). Using an IonFlux system and established Nav cell lines, they showed...

June 17, 2014

Stanford will utilize Fluxion’s IsoFlux System for patient monitoring and early cancer characterization of prostate and kidney cancers via a “liquid biopsy” from a routine blood draw

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has initiated a collaboration with the Stanford University School of Medicine focused on developing tests to help deliver more effective therapies to cancer patients. The laboratory of Dr. James Brooks is utilizing...

April 18, 2014

New kits enable mutation detection from circulating tumor cells using next-generation sequencing

SOUTH SAN FRANCISCO, Calif.  Fluxion Biosciences announced the introduction of a new series of assay kits design to enhance and complete the workflow for next-generation sequencing (NGS) using the IsoFlux System. The IsoFlux™ NGS assay kits are designed to work with circulating tumor material enriched on the IsoFlux System. They significantly increase the overall target purity of the...

February 6, 2014

New capability provides a full-service option for circulating tumor cell studies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences, Inc. announced a new capability to include full-service clinical sample procurement that will expand Fluxion’s IsoFlux Discovery Services offering. Fluxion currently offers a broad range of analytical services using its IsoFlux System for circulating tumor cell (CTC) enrichment, including qPCR and next-generation sequencing (NGS)...

January 20, 2014

New bead chemistry enables more options for targeted cell enrichment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell (CTC) and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies...

IsoFlux System demonstrates high sensitivity CTC recovery in challenging patient group

November 25, 2013

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn’s lab at Stanford University.  CTCs are cells that disseminate from primary tumors and contribute to the...

October 25, 2013

Study published in Translational Oncology highlights growing interest in non-invasive oncology diagnostics

Fluxion Biosciences announced the publication of a paper entitled “Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay”, demonstrating the capability to detect mutations in circulating tumor cells (CTCs) from cancer patients. CTCs are cells that disseminate from primary tumors and contribute to the spread of the...

October 15, 2013

QUATTRO INCREASES THROUGHPUT 4X, ENABLES HCS ENDPOINT READOUT

South San Francisco, Calif., October 15, 2013 -- Fluxion Biosciences announced today that it has launched its BioFlux Quattro High Throughput Array System for physiologically relevant live cell analysis. The system is now commercially available and shipping to customers.

The Quattro Array system is sold as a separate component and can expand the capabilities of any existing BioFlux 200 or BioFlux 1000/1000z system....

July 11, 2013

R&D Magazine's award for technical innovation recognizes IsoFlux System as a significant advance in delivering a “liquid biopsy” for cancer

July 12, 2013, South San Francisco, CA- Fluxion Biosciences, a leading provider of cell analysis platforms for research and diagnostics, today announced that it has won a 2013 R&D 100 Award for its IsoFlux™ System. The R&D 100 Award places the state-of-the-art IsoFlux System in the prestigious company of previous winners such as liquid crystal...

June 5, 2013

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, Inc. announced today that the first round of IsoFlux instruments has been delivered to customers around the world. Initially announced in November, the IsoFlux System is an automated instrument and microfluidic cartridge for high sensitivity enrichment of rare cells such as circulating tumor cells (CTCs), stem cells, and immune cells. The first 15 instrument placements included global pharma companies, emerging...

South San Francisco, Calif., Nov 13, 2012 -- Fluxion Biosciences, Inc. announced today that it has launched its IsoFlux System for circulating tumor cell (CTC) analysis at the 3rd annual World CTC Summit in Boston. The system is now commercially available and will begin shipping to customers.

The IsoFlux System is a benchtop instrument that utilizes a proprietary microfluidic technology to isolate CTCs and other rare cell types from blood samples. CTCs disseminate from primary tumors and...

Existing pre-approved FDA drugs targeting potassium channels may help in Cancer treatment

Electrical voltage patterns in healthy cells serve as a...

Exciting New T Cell Therapies Present Unique Challenges in Drug Development.

Immunotherapeutics stimulate the patient's immune system to help...

As we go through our lives, we spend a third of that time sleeping. Although this time does not amass to anything consciously productive, it is a...

A newly published paper coauthored by researchers at Fluxion and Hospices Civils de Lyon Cancer Institute tested the sensitivity and accuracy of...

Prior to their extinction, Neanderthals did not live completely in isolation. They may have interacted with enough ancestors of present-day humans...